NFATC2 and synucleinopathy: Therefore, we proposed NFAT1 as a new drug target for synucleinopathies and used 11R-VIVIT, an NFAT1 inhibitory peptide, as a tool compound to more comprehensively understand the effects of NFAT1 inhibition on microglial phenotype and interrogate the pathways involved to shed further light on its potential as a therapeutic target.